Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: A 2-year follow-up

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 4, 2011, Pages 395-400

  Chen, Chih Hsin ^a   Wu, Pei Chang ^a   Chen, Yung Jen ^a   Liu, Ya Chi ^b   Kuo, Hsi Kung ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b Yuh Ing Junior College of Health Care and Management   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; YOUNG ADULT;

EID: 79961201012     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0023     Document Type: Article

References (34)

1. Cohen, S.Y., Laroche, A., Leguen, Y., Soubrane, G., and Coscas, G.J. Etiology of choroidal neovascularization in young patients. Ophthalmology. 103:1241-1244, 1996. (Pubitemid 26282507)
2. Montero, J.A., and Ruiz-Moreno, J.M. Treatment of choroidal neovascularization in high myopia. Curr. Drug. Targets. 11:630-644, 2010.
3. Yoshida, T., Ohno-Matsui, K., Ohtake, Y., Takashima, T., Futagami, S., Baba, T., et al. Long-term visual prognosis of choroidal neovascularization in high myopia: A comparison between age groups. Ophthalmology. 109:712-719, 2002. (Pubitemid 34270128)
4. Ohno-Matsui, K., and Yoshida, T. Myopic choroidal neovascularization: Natural course and treatment. Curr. Opin. Ophthalmol. 15:197-202, 2004. (Pubitemid 38638864)
5. Blinder, K.J., Blumenkranz, M.S., Bressler, N.M., Bressler, S.B., Donato, G., Lewis, H. et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trialFVIP report no. 3. Ophthalmology. 110:667-673, 2003. (Pubitemid 36520061)
6. Wu, P., Chen, Y., Chen, C., Chen, Y.H., Kao, M.L., Shin, S.J., et al. Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: 1 and 2 year follow-up. Clin. Exp. Ophthalmol. 36:443-448, 2008.
7. Axer-Siegel, R., Ehrlich, R., Weinberger, D., et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: Visual outcome in relation to age at treatment. Am. J. Ophthalmol. 138:602-607, 2004. (Pubitemid 39420488)
8. Lam, D.S., Chan, W.M., Liu, D.T., Fan, D.S., Lai, W.W., and Chong, K.K. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization of pathologic myopia in Chinese eyes: A prospective series of 1- and 2-year follow-up. Br. J. Ophthalmol. 88:1315-1319, 2004. (Pubitemid 39312979)
9. Krebs, I., Binder, S., Stolba, U., Glittenberg, C., Brannath, W., and Goll, A. Choroidal neovascularization in pathologic myopia: Three-year results after photodynamic therapy. Am. J. Ophthalmol. 140:416-442, 2005.
10. Chan, W.M., Lai, T.Y., Liu, D.T., and Lam, D.S. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: Six-month results of a prospective pilot study. Ophthalmology. 114:2190-2196, 2007.
11. Hernandez-Rojas, M.L., Quiroz-Mercado, H., Dalma- Weiszhausz, J., Fromow-Guerra, J., Amaya-Espinosa, A., Sol's-Vivanco, A., et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina. 27:707-712, 2007. (Pubitemid 47051766)
12. Sakaguchi, H., Ikuno, Y., Gomi, F., et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br. J. Ophthalmol. 91:161-165, 2007. (Pubitemid 46202863)
13. Yamamoto, I., Rogers, A.H., Reichel, E., Yates, P.A., and Duker, J.S. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br. J. Ophthalmol. 91:157-160, 2007. (Pubitemid 46202862)
14. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin, 1 year results of a randomized clinical trial-VIP report no. 1. Ophthalmology. 108:841-852, 2007.
15. Avery, R.L., Pieramici, D.J., Rabena, M.D., Castellarin, A.A., Nasir, M.A., and Giust, M.J. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 113:363-372, 2006.
16. Gomi, F., Nishida, K., Oshima, Y., et al. Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior sub-Tenon triamcinolone. Am. J. Ophthalmol. 143:507-510, 2007.
17. Fung, A.E., Rosenfeld, P.J., and Reichel, E. The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br. J. Ophthalmol. 90:1344-1349, 2006. (Pubitemid 44702055)
18. Shima, C., Sakaguchi, H., Gomi, F., et al. Complications in patients after intravitreal injection of bevacizumab. Acta. Ophthalmol. Scand. 86:372-376, 2008.
19. Luke, M., Warga, M., Ziemssen, F., Gelisken, F., Grisanti, S., Schneider, T., et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br. J. Ophthalmol. 90:1178-1182, 2006. (Pubitemid 44351153)
20. Ziemssen, F., Luke, M., Messias, A., Beutel, J., Tatar, O., Zrenner, E., et al. Safety monitoring in bevacizumab (Avastin) treatment: Retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int. Ophthalmol. 28:101-109, 2008.
21. Gharbiya, M., Allievi, F., Mazzeo, L., and Gabrieli, C.B. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am. J. Ophthalmol. 147: 84-93, 2009.
22. Ikuno, Y., Sayanagi, K., Soga, K., Sawa, M., Tsujikawa, M., Gomi, F., et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: Oneyear results. Am. J. Ophthalmol. 147: 94-100, 2009.
23. Chan, W.M., Lai, T.Y., Liu, D.T., and Lam, D.S. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. Br. J. Ophthalmol. 93:150-154, 2009.
24. Hayashi, K., Ohno-Matsui, K., Shimada, N., Moriyama, M., Hara, W., Yoshida, T., et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes. Arch. Clin. Exp. Ophthalmol. 247:609-618, 2009.
25. Ruiz-Moreno, J.M., Gomez-Ulla, F., Montero, J.A., Ares, S., Lopez-Lopez, F., Rodriguez, M., and Fernandez, M. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: Short-term results. Eye. (Lond). 23:334-338, 2009.
26. Wu, P.C., and Chen, Y.J. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye. (Lond). 23:2042-2045, 2009.
27. Silva, R.M., Ruiz-Moreno, J.M., Nascimento, J., Carneiro, A., Rosa, P., Barbosaa, A., et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina. 28:1117-1123, 2008.
28. Costa, R.A., Jorge, R., Calucci, D., Cardillo, J.A., Melo, L.A., Jr., and Scott, I.U. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase 1 dose-escalation study. Invest. Ophthalmol. Vis. Sci. 47: 4569-4578, 2006. (Pubitemid 46579387)
29. Yoganathan, P., Fastenberg, D.M., and Ferrone, P.J. Intravitreal Bevacizumab 2.5 versus 1.25 mg in Exudative Age- Related Macular Degeneration: Safety and Efficacy. Program and Abstracts of the Association for Research in Vision and Ophthalmology. Fort Lauderdale: Florida; 2007, Abstract 166.
30. Ruiz-Moreno, J.M., Montero, J.A., Gomez-Ulla, F., and Ares, S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br. J. Ophthalmol. 93:448-451, 2009.
31. Voykov, B., Gelisken, F., Inhoffen, W., Voelker, M., Bartz- Schmidt, K.U., and Ziemssen, F. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years? Graefes. Arch. Clin. Exp. Ophthalmol. 248:543-550, 2010.
32. Kojima, A., Ohno-Matsui, K., Teramukai, S., et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes. Arch. Clin. Exp. Ophthalmol. 244:1474-1479, 2006. (Pubitemid 44741259)
33. Montero, J.A., and Ruiz-Moreno, J.M. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br. J. Ophthalmol. 87:173-176, 2003. (Pubitemid 36152743)
34. Ruiz-Moreno, J.M., Amat, P., Montero, J.A., and Lugo, F. Photodynamic therapy to treat choroidal neovascularisation in highly myopic patients: 4 years' outcome. Br. J. Ophthalmol. 92:792-794, 2008. (Pubitemid 351839570)